Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas

Schwannomas exhibit distinct size-dependent gene-expression patterns

(2015) Ruty Mehrian-Shai et al.   Future Oncology

Targeting the translation machinery in cancer

(2015) Mamatha Bhat et al.   NATURE REVIEWS DRUG DISCOVERY

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape

(2015) A Modelska et al.   Cell Death & Disease

Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer

(2015) A. Wiegering et al.   Cancer Discovery

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

(2015) John T. Patton et al.   Oncotarget

Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

(2014) V. Gandhi et al.   CLINICAL CANCER RESEARCH

MicroRNAs Trigger Dissociation of eIF4AI and eIF4AII from Target mRNAs in Humans

(2014) Akira Fukao et al.   MOLECULAR CELL

Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species

(2014) Li Pan et al.   NATURAL PRODUCT REPORTS

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

(2014) Andrew L. Wolfe et al.   NATURE

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

(2014) Marco Giovannini et al.   NEURO-ONCOLOGY

Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors

(2014) F. Panzuto et al.   ONCOLOGIST

Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex

(2013) Heather Sadlish et al.   ACS Chemical Biology

Synthesis of Biotinylated Episilvestrol: Highly Selective Targeting of the Translation Factors eIF4AI/II

(2013) Jennifer M. Chambers et al.   ORGANIC LETTERS

Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer

(2013) Takayuki Kogure et al.   PLoS One

Tight Coordination of Protein Translation and HSF1 Activation Supports the Anabolic Malignant State

(2013) S. Santagata et al.   SCIENCE

Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth

(2012) S. S. Burns et al.   CANCER RESEARCH

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

(2012) L. Alinari et al.   CLINICAL CANCER RESEARCH

Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors

(2012) Matthew L. Bush et al.   OTOLOGY & NEUROTOLOGY

Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2

(2012) Scott R. Plotkin et al.   OTOLOGY & NEUROTOLOGY

A cellular response linking eIF4AI activity to eIF4AII transcription

(2012) G. Galicia-Vazquez et al.   RNA

Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography–Tandem Mass Spectrometry

(2011) U. V. R. Vijaya Saradhi et al.   AAPS Journal

The Relevance of Higher Plants in Lead Compound Discovery Programs

(2011) A. Douglas Kinghorn et al.   JOURNAL OF NATURAL PRODUCTS

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas

(2011) M. L. Bush et al.   NEURO-ONCOLOGY

Isolation and Characterization of Minor Analogues of Silvestrol and Other Constituents from a Large-Scale Re-collection ofAglaia foveolata

(2010) Li Pan et al.   JOURNAL OF NATURAL PRODUCTS

DDX3 Regulates Cell Growth through Translational Control of Cyclin E1

(2010) M.-C. Lai et al.   MOLECULAR AND CELLULAR BIOLOGY

The mechanism of eukaryotic translation initiation and principles of its regulation

(2010) Richard J. Jackson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

(2010) Scott R. Plotkin et al.   OTOLOGY & NEUROTOLOGY

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways

(2009) Daniela Katz et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1

(2009) Hilde Brems et al.   LANCET ONCOLOGY

Altering Chemosensitivity by Modulating Translation Elongation

(2009) Francis Robert et al.   PLoS One

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET